$0.14
-0.05 (-27.93%)
Open$0.18
Previous Close$0.20
Day High$0.18
Day Low$0.12
52W High$1,979.68
52W Low—
Volume—
Avg Volume4.29M
Market Cap105.5K
P/E Ratio—
EPS$-14,962.54
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+9,501.7% upside
Current
$0.14
$0.14
Target
$13.50
$13.50
$9.80
$13.50 avg
$19.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.18B | 10.47B | 180.5K |
| Net Income | -2,873,510,358,333 | -2,421,497,492,977 | -19,611 |
| Profit Margin | -25,708.3% | -24,422.8% | -10.9% |
| EBITDA | -2,290,571,274,425 | -2,037,493,174,816 | -25,362 |
| Free Cash Flow | — | — | -13,693 |
| Rev Growth | +6.8% | +6.8% | +10.1% |
| Debt/Equity | 0.65 | 0.65 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |